Malini B. DeSilva

Malini B. DeSilva

Auto-generated profile, based on publicly available information

Malini B. DeSilva

Department of Research, HealthPartners Institute , Minneapolis, Minnesota

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2021 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
MDMalini B. DeSilva
Malini B. DeSilva
JHJacob Haapala
Jacob Haapala
GVGabriela Vazquez-Benitez
Gabriela Vazquez-Benitez
MDMatthew F. Daley
Matthew F. Daley
JNJames D. Nordin
James D. Nordin
EKElyse O. Kharbanda
Elyse O. Kharbanda
On-time administration of vaccines is essential for the prevention of certain communicable diseases. The childhood immunization schedule recommended by the US Advisory Committee on Immunization Practices protects children against 14 infectious diseases before their second birthday.1 Routine vaccines for children and adolescents induce long-term immunity for many infectious diseases and prevent cervical, oropharyngeal, and other cancers. Additionally, routine childhood vaccines reduce the transmission of infections within communities.2-4 Vaccines are typically administered to children during well-child visits that occur at specific intervals throughout infancy, childhood, and adolescence.5 Documentation of vaccines is generally required for daycare or school entry,6 and adherence with vaccination guidelines is a quality measure for health systems.7 As such, prior to the COVID-19 pandemic, the US maintained high coverage for most recommended pediatric vaccines.8-11

1 June 2017 in Vaccine
Verified
Journal Article
Closed access
MDMalini DeSilva
Malini DeSilva
GVGabriela Vazquez-Benitez
Gabriela Vazquez-Benitez
JNJames D. Nordin
James D. Nordin
HLHeather S. Lipkind
Heather S. Lipkind
NKNicola P. Klein
Nicola P. Klein
EKElyse O. Kharbanda
Elyse O. Kharbanda

14 July 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MDMalini DeSilva
Malini DeSilva
JHJacob Haapala
Jacob Haapala
GVGabriela Vazquez-Benitez
Gabriela Vazquez-Benitez
KVKimberly K. Vesco
Kimberly K. Vesco
MDMatthew F. Daley
Matthew F. Daley
EKElyse O. Kharbanda
Elyse O. Kharbanda
Pregnant women with symptomatic coronavirus disease 2019 (Covid-19) have a higher risk of adverse outcomes than do women who are not pregnant.1,2 In part because of these findings, Covid-19 vaccination has been recommended for pregnant women. However, uptake has been lower in pregnant women than among women who are not pregnant.3,4 The concern of many women regarding safety remains a barrier to maternal vaccination.

9 March 2022 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
PWPatricia F. Walker
Patricia F. Walker
ASAnn M. Settgast
Ann M. Settgast
MDMalini B. DeSilva
Malini B. DeSilva
: Clinicians in the United States are trained to screen for cancer based on patient age, gender, family history, and environmental risk factors such as smoking. These cancers generally include, breast, cervical, colon, lung, and prostate cancers. We know that refugees and other immigrants to the United States experience dramatic disparities in cancer screening. Additionally, many immigrants experience elevated risks from infection-attributable cancers due to their country or region of origin. U.S.- based clinicians may not routinely consider these unique risk factors. Although this article focuses on refugees, it is also intended to guide clinicians caring for other foreign-born immigrant groups living in the United States (hereafter referred to as “immigrants”). The document contains two sections: 1) special considerations for U.S. Preventive Services Task Force guidelines cancer screening recommendations in immigrants and 2) cancer risks and screening recommendation unique to certain immigrant groups. Disparities in cancer screening and prevalence are often greater for specific immigrant groups than for broader racial or ethnic groups (e.g., Black, Asian, Hispanic) into which they may fit. Disaggregation of data by language or country of origin is useful to identify such disparities and to design intervention opportunities within specific communities that are culturally distinct and/or who have different environmental exposures. Unique cancer risks and disparities in screening support a nuanced approach to cancer screening for immigrant and refugee populations, which is the focus of this narrative review.

4 December 2024 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
MTMark W Tenforde
Mark W Tenforde
EREmily L Reeves
Emily L Reeves
ZWZachary A Weber
Zachary A Weber
STSara Tartof
Sara Tartof
NKNicola P Klein
Nicola P Klein
SGShikha Garg
Shikha Garg
Background: The 2023–2024 influenza season had predominant influenza A(H1N1)pdm09 virus activity, but A(H3N2) and B viruses cocirculated. Seasonal influenza vaccine strains were well-matched to these viruses. Methods: Using healthcare encounters data from health systems in 8 US states, we evaluated influenza vaccine effectiveness (VE) against influenza-associated medical encounters from October 2023 to April 2024. Using a test-negative design, we compared the odds of vaccination between patients with an acute respiratory illness who tested positive (cases) versus negative (controls) for influenza by molecular assay, adjusting for confounders. VE was stratified by age group, influenza type (overall, influenza A, influenza B), and care setting (hospitalization, emergency department or urgent care [ED/UC] encounter). Results: Overall, 74 000 encounters in children and adolescents aged 6 months–17 years (3479 hospitalizations, 70 521 ED/UC encounters) and 267 606 in adults aged ≥18 years (66 828 hospitalizations, 200 778 ED/UC encounters) were included. Across care settings, among children and adolescents, 15% (2758/17 833) of cases versus 32% (18 240/56 167) of controls had received vaccination. Among adults, 25% (11 632/46 614) of cases versus 44% (97 811/220 992) of controls across care settings had received vaccination. VE was 58% (95% confidence interval [95% CI], 44–69) against hospitalization and 58% (95% CI, 56–60) against ED/UC encounters for children and adolescents, and 39% (95% CI, 35–43) against hospitalization and 47% (95% CI, 46–49) against ED/UC encounters for adults. Across age groups, VE was higher against influenza B than influenza A. Conclusions: Influenza vaccines provided protection against influenza-associated illness across health care settings and age groups during the 2023–2024 influenza season.

1 January 2020 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
NTNicola D. Thompson
Nicola D. Thompson
APAustin Penna
Austin Penna
TETaniece R. Eure
Taniece R. Eure
WBWendy M. Bamberg
Wendy M. Bamberg
GBGrant Barney
Grant Barney
SMShelley S. Magill
Shelley S. Magill